Universal Biosensors Management

Management Kriterienprüfungen 2/4

Universal Biosensors CEO ist John Sharman , ernannt in Jan 2020, hat eine Amtszeit von 4.83 Jahren. Die jährliche Gesamtvergütung beträgt A$883.80K , bestehend aus 58.3% Gehalt und 41.7% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.69% der Aktien des Unternehmens, im Wert von A$247.07K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.8 Jahre bzw. 8.5 Jahre.

Wichtige Informationen

John Sharman

Geschäftsführender

AU$883.8k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	58.3%
Amtszeit als Geschäftsführer	4.8yrs
Eigentum des Geschäftsführers	0.7%
Durchschnittliche Amtszeit des Managements	3.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	8.5yrs

Jüngste Management Updates

Recent updates

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Nov 09

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

May 03

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Jan 12

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Oct 10

Companies Like Universal Biosensors (ASX:UBI) Are In A Position To Invest In Growth

Apr 28

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

May 13

Should You Take Comfort From Insider Transactions At Universal Biosensors, Inc. (ASX:UBI)?

Feb 24

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

Jan 20

The Universal Biosensors (ASX:UBI) Share Price Has Gained 95% And Shareholders Are Hoping For More

Dec 15

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von John Sharman im Vergleich zu den Einnahmen von Universal Biosensors verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	-AU$12m
Jun 30 2024	n/a	n/a	-AU$12m
Mar 31 2024	n/a	n/a	-AU$6m
Dec 31 2023	AU$884k	AU$515k	-AU$7m
Sep 30 2023	n/a	n/a	-AU$18m
Jun 30 2023	n/a	n/a	-AU$20m
Mar 31 2023	n/a	n/a	-AU$26m
Dec 31 2022	AU$532k	AU$483k	-AU$27m
Sep 30 2022	n/a	n/a	-AU$19m
Jun 30 2022	n/a	n/a	-AU$16m
Mar 31 2022	n/a	n/a	-AU$14m
Dec 31 2021	AU$3m	AU$480k	-AU$11m
Sep 30 2021	n/a	n/a	-AU$7m
Jun 30 2021	n/a	n/a	-AU$6m
Mar 31 2021	n/a	n/a	-AU$8m
Dec 31 2020	AU$696k	AU$271k	-AU$8m

Vergütung im Vergleich zum Markt: JohnDie Gesamtvergütung ($USD573.89K) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Australian ($USD298.55K).

Entschädigung vs. Einkommen: JohnDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

John Sharman (58 yo)

4.8yrs

Amtszeit

AU$883,796

Vergütung

Mr. John Stewart Sharman, M.App.Fin, CA, BEcon has been the Chief Executive Officer at Universal Biosensors, Inc. since 2020. He served as Non-Executive Director at Cann Group Limited from April 27, 2021 t...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
John Sharman	Chief Executive Officer	4.8yrs	AU$883.80k	0.69% A$ 247.1k
Salesh Balak	CFO & Company Secretary	18yrs	AU$366.11k	0.13% A$ 46.6k
Nicholas Bliesner	Head of Operations	3.5yrs	keine Daten	keine Daten
Luke Cossins	Head of Research & Development	3.8yrs	keine Daten	keine Daten
Ann Chew	Head of People Strategy & Culture	2.8yrs	keine Daten	keine Daten

3.8yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: UBIDas Führungsteam des Unternehmens gilt als erfahren (3.8 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Craig Coleman	Non-Executive Director	8.4yrs	AU$86.40k	0.33% A$ 116.5k
David Hoey	Independent Non-Executive Director	8.7yrs	AU$77.60k	0.22% A$ 79.5k
Judith Smith	Independent Non-Executive Director	9.7yrs	AU$85.94k	0.15% A$ 53.1k
Mark Crowther	Member of the Scientific Advisory Panel	no data	keine Daten	keine Daten
Graham McLean	Independent Non-Executive Chairman	2.7yrs	AU$111.33k	0.36% A$ 129.6k
David Church	Member of the Scientific Advisory Panel	no data	keine Daten	keine Daten
John Loftus	Member of the Scientific Advisory Panel	no data	keine Daten	keine Daten
Simon Corrie	Member of the Scientific Advisory Panel	no data	keine Daten	keine Daten
Steve Kitchen	Member of the Scientific Advisory Panel	no data	keine Daten	keine Daten
Sam Schulman	Member of the Scientific Advisory Panel	no data	keine Daten	keine Daten
Davide Matino	Member of the Scientific Advisory Panel	no data	keine Daten	keine Daten
Eric Wilkes	Member of the Scientific Advisory Panel	no data	keine Daten	keine Daten

8.5yrs

Durchschnittliche Betriebszugehörigkeit

59yo

Durchschnittliches Alter

Erfahrener Vorstand: UBIDie Vorstandsmitglieder gelten als erfahren (8.5 Jahre durchschnittliche Amtszeit).

Universal Biosensors Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Non-Executive Director recently bought AU$50k worth of stock

Universal Biosensors, Inc., Annual General Meeting, May 30, 2024

Universal Biosensors, Inc., Annual General Meeting, Apr 10, 2024

Chief Executive Officer exercised options to buy AU$259k worth of stock.

Universal Biosensors, Inc. Announces Chairman Changes

Non-Executive Chairman recently bought AU$54k worth of stock

Recent updates

New major risk - Financial position

Third quarter 2024 earnings released: AU$0.011 loss per share (vs AU$0.012 loss in 3Q 2023)

Universal Biosensors, Inc. to Report First Half, 2024 Results on Aug 09, 2024

Second quarter 2024 earnings released: AU$0.014 loss per share (vs AU$0.007 profit in 2Q 2023)

Non-Executive Director recently bought AU$50k worth of stock

First quarter 2024 earnings released: AU$0.016 loss per share (vs AU$0.018 loss in 1Q 2023)

Universal Biosensors, Inc., Annual General Meeting, May 30, 2024

New minor risk - Shareholder dilution

Universal Biosensors, Inc., Annual General Meeting, Apr 10, 2024

New minor risk - Shareholder dilution

Chief Executive Officer exercised options to buy AU$259k worth of stock.

Universal Biosensors, Inc. has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Universal Biosensors, Inc. to Report Fiscal Year 2023 Results on Mar 07, 2024

Universal Biosensors, Inc. has filed a Follow-on Equity Offering in the amount of AUD 10 million.

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Third quarter 2023 earnings released: AU$0.012 loss per share (vs AU$0.024 loss in 3Q 2022)

New minor risk - Financial position

Second quarter 2023 earnings released: EPS: AU$0.007 (vs AU$0.024 loss in 2Q 2022)

New minor risk - Share price stability

First quarter 2023 earnings released: AU$0.018 loss per share (vs AU$0.025 loss in 1Q 2022)

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Full year 2022 earnings: EPS and revenues miss analyst expectations

Universal Biosensors, Inc. Launches New Product, Fructose Test for Sentia

Universal Biosensors, Inc. completes Xprecia Prime clinical trial in USA

Universal Biosensors, Inc. Announces Chairman Changes

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Non-Executive Chairman recently bought AU$54k worth of stock

Price target increased to AU$1.15

Third quarter 2022 earnings released: AU$0.024 loss per share (vs AU$0.016 loss in 3Q 2021)

Price target increased to AU$1.15

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Non-Executive Chairman recently bought AU$56k worth of stock

Consensus revenue estimates fall by 19%

Second quarter 2022 earnings released: AU$0.024 loss per share (vs AU$0.01 loss in 2Q 2021)

Consensus revenue estimates fall by 10%

Universal Biosensors, Inc. has completed a Follow-on Equity Offering in the amount of AUD 20.007467 million.

First quarter 2022 earnings released: AU$0.025 loss per share (vs AU$0.008 loss in 1Q 2021)

Universal Biosensors, Inc., Annual General Meeting, Jun 21, 2022

Companies Like Universal Biosensors (ASX:UBI) Are In A Position To Invest In Growth

Price target increased to AU$1.25

Forecast to breakeven in 2024

Universal Biosensors, Inc. Announces Interim Results from the Peter Mac Sponsored Tn Antigen Development Clinical Study

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Universal Biosensors, Inc. Announces the Launch of the Sentia Malic Acid Test into the Global Wine Market

Second quarter 2021 earnings released: AU$0.01 loss per share (vs AU$0.017 loss in 2Q 2020)

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

First quarter 2021 earnings released: AU$0.008 loss per share (vs AU$0.008 loss in 1Q 2020)

Independent Non-Executive Director has left the company

Universal Biosensors, Inc. Announces Resignation of Marshall Heinberg as Director

Full year 2020 earnings released: AU$0.043 loss per share (vs AU$0.027 loss in FY 2019)

Should You Take Comfort From Insider Transactions At Universal Biosensors, Inc. (ASX:UBI)?

Universal Biosensors, Inc. Enters into Non-Exclusive Distribution Agreement with Enartis Inc

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

New 90-day high: AU$0.54

The Universal Biosensors (ASX:UBI) Share Price Has Gained 95% And Shareholders Are Hoping For More

Universal Biosensors, Inc. Releases SENTIA

New 90-day high: AU$0.34

Independent Non-Executive Director recently bought AU$62k worth of stock

Universal Biosensors, Inc. Announces Appointment of Promedeus s.r.o. as Its New Distribution Partner in Czech Republic and Slovak Republic

New 90-day high - AU$0.33

New 90-day high - AU$0.27

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit